How to Build a Biotech with Celine Halioua, Founder and CEO of Loyal

TL;DR

Loyal, a biotech company, aims to extend the lifespan of dogs through drugs that slow their rate of aging, based on the genetic connection between growth hormone and dog size. The founder, Selene Halwa, shares her journey and insights on longevity, FDA approval, and the challenges of building a biotech startup.

Transcript

had been really interested in this biology around igf1 and growth hormones where if you modified this Gene which gave him really really low levels of growth hormone you actually made the worm lip significantly longer and there had been all this foundational work for decades showing you know reducing growth hormone extending lifespan at the same tim... Read More

Key Insights

• ☠️ Loyal's focus on extending the lifespan of dogs through drugs that slow their rate of aging is a unique approach in the field of biotech.
• 🤵 The genetic connection between growth hormone and dog size provides a valuable insight for developing lifespan extension drugs.
• 🏑 Choosing the FDA approval route adds credibility to the longevity field and helps establish the legitimacy of lifespan extension drugs.
• 👍 The challenges of getting lifespan extension drugs approved include long-term studies and the complex nature of measuring lifespan extension in humans.
• ☠️ The rate of growth and the ability to learn and adapt quickly are essential factors in determining a person's potential for growth within an organization.
• 🥺 Building a biotech startup requires a combination of technical competence and the ability to communicate and lead in a Silicon Valley manner.
• 🥺 Failing in fundraising can be a learning opportunity, leading to improvements and a clearer path to success in the future.

Questions & Answers

Q: What is Loyal's approach to extending lifespan in dogs?

Loyal aims to slow the rate of aging in dogs through drugs that reduce the concentration of growth hormone and igf1, which are associated with accelerated aging and shorter lifespan in big dogs. By extending their healthy years, Loyal hopes to increase their overall lifespan as well.

Q: Why did Selene choose the FDA approval route for Loyal's drugs?

Selene wanted to establish the legitimacy of the longevity field and show that lifespan extension drugs are not just a marketing gimmick. By subjecting Loyal's drugs to FDA approval, she aimed to provide objective proof that they are safe and effective for extending lifespan, increasing the credibility of the field.

Q: What challenges are involved in getting lifespan extension drugs approved?

The major challenge is the time it takes to show the efficacy of the drugs in lifespan extension. Long-term studies spanning several decades are required, which is logistically and financially difficult for startups. Additionally, measuring lifespan extension in humans is complex, as it involves following individuals for a long time and accounting for various factors.

Q: How does Loyal measure the success of its drugs in extending lifespan in dogs?

Loyal measures the success of its drugs by observing changes in lifespan as well as in well-established indicators of aging, such as cognitive decline and functional decline. The goal is to not only lengthen lifespan but also improve the overall quality of life for dogs.

Summary & Key Takeaways

• Selene Halwa, founder and CEO of Loyal, shares her interest in the biology of growth hormone and lifespan extension, which led to the discovery of the genetic connection between growth hormone and dog size.

• Loyal focuses on developing drugs to slow the rate of aging in dogs, with the goal of helping them live longer and healthier lives. The company aims to create a daily pill that reduces the risk of multiple age-related diseases simultaneously.

• Selene explains why she chose the FDA approval route, the challenges of getting lifespan extension drugs approved, and the potential impact of such drugs on human longevity.